TWI556828B - 抗－α４β７抗體之調配物 - Google Patents

抗－α４β７抗體之調配物 Download PDF

Info

Publication number
TWI556828B
TWI556828B TW101115712A TW101115712A TWI556828B TW I556828 B TWI556828 B TW I556828B TW 101115712 A TW101115712 A TW 101115712A TW 101115712 A TW101115712 A TW 101115712A TW I556828 B TWI556828 B TW I556828B
Authority
TW
Taiwan
Prior art keywords
antibody
formulation
seq
dose
weeks
Prior art date
Application number
TW101115712A
Other languages
English (en)
Chinese (zh)
Other versions
TW201247223A (en
Inventor
艾文Ｈ 福克斯
凱薩琳 史可茲
科沙納德Ｍ 瓦加
維斯亞納桑 派倫尼亞潘恩
傑森 布朗
威洛 迪魯茲歐
諾貝爾Ｔ 楚恩
Original Assignee
千禧製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI556828(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 千禧製藥公司 filed Critical 千禧製藥公司
Publication of TW201247223A publication Critical patent/TW201247223A/zh
Application granted granted Critical
Publication of TWI556828B publication Critical patent/TWI556828B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Endocrinology (AREA)
TW101115712A 2011-05-02 2012-05-02 抗－α４β７抗體之調配物 TWI556828B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481533P 2011-05-02 2011-05-02
US201161550545P 2011-10-24 2011-10-24
US201261585859P 2012-01-12 2012-01-12

Publications (2)

Publication Number Publication Date
TW201247223A TW201247223A (en) 2012-12-01
TWI556828B true TWI556828B (zh) 2016-11-11

Family

ID=46085207

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105130046A TWI664978B (zh) 2011-05-02 2012-05-02 抗－α４β７抗體之用途
TW107138209A TWI664980B (zh) 2011-05-02 2012-05-02 抗-α4β7抗體之用途
TW101115712A TWI556828B (zh) 2011-05-02 2012-05-02 抗－α４β７抗體之調配物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW105130046A TWI664978B (zh) 2011-05-02 2012-05-02 抗－α４β７抗體之用途
TW107138209A TWI664980B (zh) 2011-05-02 2012-05-02 抗-α4β7抗體之用途

Country Status (42)

Country Link
US (16) US9764033B2 (enExample)
EP (4) EP2704798B1 (enExample)
JP (7) JP6190360B2 (enExample)
KR (8) KR20140145953A (enExample)
CN (4) CN108129565B (enExample)
AR (1) AR086237A1 (enExample)
AU (7) AU2012250873B2 (enExample)
BR (1) BR112013028424A2 (enExample)
CA (2) CA2834867C (enExample)
CL (2) CL2013003146A1 (enExample)
CO (1) CO6801647A2 (enExample)
CR (1) CR20130677A (enExample)
CY (1) CY1119435T1 (enExample)
DK (2) DK2704798T3 (enExample)
DO (1) DOP2013000253A (enExample)
EA (1) EA032729B1 (enExample)
EC (2) ECSP13013050A (enExample)
ES (2) ES3016382T3 (enExample)
FI (1) FI3329965T3 (enExample)
GE (1) GEP201706734B (enExample)
HK (1) HK1249466A1 (enExample)
HR (2) HRP20250472T1 (enExample)
HU (2) HUE071510T2 (enExample)
IL (5) IL275038B2 (enExample)
LT (2) LT2704798T (enExample)
MA (1) MA35136B1 (enExample)
ME (1) ME02859B (enExample)
MX (4) MX383317B (enExample)
MY (2) MY172735A (enExample)
PE (2) PE20141175A1 (enExample)
PH (3) PH12013502236A1 (enExample)
PL (2) PL3329965T3 (enExample)
PT (2) PT3329965T (enExample)
RS (2) RS66809B1 (enExample)
SG (1) SG194652A1 (enExample)
SI (2) SI3329965T1 (enExample)
SM (2) SMT201700508T1 (enExample)
TW (3) TWI664978B (enExample)
UA (2) UA116189C2 (enExample)
UY (1) UY34053A (enExample)
WO (1) WO2012151248A2 (enExample)
ZA (3) ZA201308069B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
AU2012250872B2 (en) 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
LT2968588T (lt) * 2013-03-15 2019-05-10 AbbVie Deutschland GmbH & Co. KG Anti-egfr antikūnų vaistų konjugatų kompozicijos
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN106456784A (zh) * 2014-04-16 2017-02-22 拜康有限公司 包含摩尔过量的山梨醇的稳定蛋白质制剂
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
HK1249549A1 (en) * 2015-08-11 2018-11-02 Osaka University Antibody
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
CN117298268A (zh) * 2016-03-14 2023-12-29 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
CA3017743A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
WO2017158393A1 (en) * 2016-03-18 2017-09-21 Oslo University Hospital Hf Methods of treating graft-versus-host disease
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
MY197672A (en) * 2016-10-07 2023-07-03 Regeneron Pharma Room temperature stable lyophilized protein
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
EP3558391B1 (en) * 2016-12-23 2022-02-02 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
JP2020517671A (ja) 2017-04-28 2020-06-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小児の障害を処置する方法
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20200011457A (ko) * 2017-05-26 2020-02-03 밀레니엄 파머슈티컬스 인코퍼레이티드 만성 맹낭염의 치료 방법
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
EP3773696A4 (en) * 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Stable formulations of therapeutic antibody
SG11202009874QA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Antibody formulation
SG11202011651SA (en) 2018-05-31 2020-12-30 Ono Pharmaceutical Co Biomarkers for determining the effectiveness of immune checkpoint inhibitors
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN109239335A (zh) * 2018-09-11 2019-01-18 广州万孚生物技术股份有限公司 联检试纸条及其制备方法
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
PL439809A1 (pl) * 2019-06-10 2022-12-05 Takeda Pharmaceutical Company Limited Metody wytwarzania przeciwciała anty-alfa4beta7
MX2021015302A (es) * 2019-06-10 2022-01-18 Takeda Pharmaceuticals Co Metodos de purificacion de anticuerpos y composiciones de estos.
CA3143246A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Cell culture methods and compositions for antibody production
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CN113577281A (zh) * 2020-04-30 2021-11-02 中国科学院分子细胞科学卓越创新中心 调控整合素β亚基的试剂和方法
AR122983A1 (es) 2020-07-16 2022-10-19 Abbvie Inc ANTICUERPOS ANTI-a4b7
EP4281045A4 (en) * 2021-01-20 2024-12-18 Dr. Reddy's Laboratories Limited LYOPHILIZED ANTIBODY FORMULATIONS AND RELATED METHODS
BR112023022811A2 (pt) * 2021-05-07 2024-01-16 Dr Reddys Laboratories Ltd Formulações farmacêuticas de um anticorpo alfa-4-beta-7 de alta concentração e de vedolizumabe de alta concentração, e, métodos para controlar a formação de partículas subvisíveis em um anticorpo alfa-4-beta-7 e de variantes de carga ou agregados ou fragmentação do anticorpo em uma composição de anticorpo alfa-4-beta-7 de alta concentração, para controlar a opalescência em uma composição de anticorpo alfa-4-beta-7 de alta concentração e para preparar uma composição de anticorpo alfa-4-beta-7
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025133872A1 (en) * 2023-12-19 2025-06-26 Intas Pharmaceuticals Ltd. Method for reducing oxidation levels in vedolizumab during cell culture process
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US774216A (en) 1903-11-19 1904-11-08 Alexander F Ward Machine for pointing and lapping hoops.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0303463B1 (en) 1987-08-11 1994-11-30 The Board Of Trustees Of The Leland Stanford Junior University Method to control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
WO1995019790A1 (en) 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
MX9706049A (es) 1995-02-10 1998-02-28 Leukosite Inc Adresinas vasculares mucosas y sus usos.
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
SI1485127T1 (sl) * 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
PT1562940E (pt) 2002-11-18 2007-07-23 Chemocentryx Inc Sulfonamidas de arilo.
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
HRP20120171T1 (hr) * 2004-09-03 2012-03-31 Genentech Humanizirani anti-beta 7 antagonisti i njihove uporabe
CA2629147A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
BRPI0710826A2 (pt) 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
TW200833357A (en) 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
AU2007331712A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
CN102388068B (zh) 2009-03-20 2015-05-20 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
KR20120027031A (ko) * 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
AU2012236304C1 (en) 2011-03-31 2017-01-05 Genentech, Inc. Methods of administering beta7 integrin antagonists
AU2012250872B2 (en) 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
US11389533B2 (en) * 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Pharm Sci. 2001 Mar;90(3):310-21 *

Also Published As

Publication number Publication date
AU2016231469A1 (en) 2016-10-06
CA3028209A1 (en) 2012-11-08
HRP20171432T1 (hr) 2017-11-03
TW201247223A (en) 2012-12-01
US10004808B2 (en) 2018-06-26
US20120282249A1 (en) 2012-11-08
SMT202500218T1 (it) 2025-07-22
IL267668A (en) 2019-08-29
MX383317B (es) 2025-03-13
ZA201308069B (en) 2016-01-27
CA2834867C (en) 2019-02-12
US20250000981A1 (en) 2025-01-02
EA032729B1 (ru) 2019-07-31
CA2834867A1 (en) 2012-11-08
JP6190360B2 (ja) 2017-08-30
AU2019201926A1 (en) 2019-04-11
CN108187042A (zh) 2018-06-22
JP6878489B2 (ja) 2021-05-26
KR20170116217A (ko) 2017-10-18
CN108079291B (zh) 2022-04-08
PH12013502236A1 (en) 2014-01-06
AU2012250873A1 (en) 2013-05-09
GEP201706734B (en) 2017-09-25
US20220370617A1 (en) 2022-11-24
ME02859B (me) 2018-04-20
HRP20250472T1 (hr) 2025-06-06
TWI664978B (zh) 2019-07-11
ES3016382T3 (en) 2025-05-09
UY34053A (es) 2012-11-30
JP7492057B2 (ja) 2024-05-28
IL275038B2 (en) 2023-03-01
JP6534415B2 (ja) 2019-06-26
KR102275603B1 (ko) 2021-07-08
MX356827B (es) 2018-06-15
US20160340431A1 (en) 2016-11-24
US20180289811A1 (en) 2018-10-11
US20170002078A1 (en) 2017-01-05
CN108129565A (zh) 2018-06-08
CL2013003146A1 (es) 2014-07-25
KR20210084711A (ko) 2021-07-07
TW201718012A (zh) 2017-06-01
PH12018500030A1 (en) 2018-10-15
KR101923378B1 (ko) 2018-11-29
KR20220154834A (ko) 2022-11-22
DK2704798T3 (en) 2017-10-23
PL2704798T3 (pl) 2017-12-29
ECSP13013050A (es) 2014-01-31
AU2022231726A1 (en) 2022-10-06
JP2019108400A (ja) 2019-07-04
CR20130677A (es) 2014-10-07
EP3329965A3 (en) 2018-12-12
US20160340432A1 (en) 2016-11-24
JP2018150388A (ja) 2018-09-27
EP3329965B1 (en) 2025-03-19
EA201391614A1 (ru) 2014-07-30
IL267668B (en) 2020-10-29
US20250041424A1 (en) 2025-02-06
LT3329965T (lt) 2025-06-10
US20140377251A1 (en) 2014-12-25
AR086237A1 (es) 2013-11-27
EP3263178A1 (en) 2018-01-03
CY1119435T1 (el) 2018-03-07
JP2017137351A (ja) 2017-08-10
JP2014514346A (ja) 2014-06-19
ES2645187T3 (es) 2017-12-04
JP2021113223A (ja) 2021-08-05
WO2012151248A2 (en) 2012-11-08
EP4378484A3 (en) 2024-09-04
HUE036663T2 (hu) 2018-07-30
HUE071510T2 (hu) 2025-09-28
PH12018500030B1 (en) 2022-05-04
US9764033B2 (en) 2017-09-19
US12171832B2 (en) 2024-12-24
AU2016231469B2 (en) 2018-12-20
US9663579B2 (en) 2017-05-30
US20250295786A1 (en) 2025-09-25
US20190231878A1 (en) 2019-08-01
JP6473845B2 (ja) 2019-02-20
US20250288679A1 (en) 2025-09-18
MX348814B (es) 2017-06-30
US12053526B2 (en) 2024-08-06
MX2013012724A (es) 2013-12-06
DK3329965T3 (da) 2025-04-07
IL296847A (en) 2022-11-01
US10143752B2 (en) 2018-12-04
BR112013028424A2 (pt) 2021-05-04
JP2023076616A (ja) 2023-06-01
AU2012250873B2 (en) 2016-07-07
KR102096484B1 (ko) 2020-04-02
MX2021006723A (es) 2022-05-03
PT2704798T (pt) 2017-11-14
EP4378484A2 (en) 2024-06-05
FI3329965T3 (fi) 2025-04-30
PL3329965T3 (pl) 2025-04-28
IL229104A0 (en) 2013-12-31
MA35136B1 (fr) 2014-05-02
CO6801647A2 (es) 2013-11-29
KR101923371B1 (ko) 2018-11-29
EP2704798A2 (en) 2014-03-12
PE20190405A1 (es) 2019-03-14
CL2017000830A1 (es) 2017-12-22
KR20180050435A (ko) 2018-05-14
AU2018278866B2 (en) 2020-07-09
EP3329965A1 (en) 2018-06-06
KR20180127540A (ko) 2018-11-28
TW201906631A (zh) 2019-02-16
ECSP22034515A (es) 2022-05-31
UA126545C2 (uk) 2022-11-02
HK1256106A1 (en) 2019-09-13
AU2022231726B2 (en) 2025-01-09
PE20141175A1 (es) 2014-09-25
RS66809B1 (sr) 2025-06-30
LT2704798T (lt) 2017-10-25
US20190076532A1 (en) 2019-03-14
US20210052733A1 (en) 2021-02-25
KR102465394B1 (ko) 2022-11-09
SI2704798T1 (sl) 2017-12-29
AU2025202434A1 (en) 2025-04-24
AU2020250249A1 (en) 2020-11-05
CA3028209C (en) 2021-01-05
CN103608071A (zh) 2014-02-26
AU2020250249B2 (en) 2022-10-06
TWI664980B (zh) 2019-07-11
CN108129565B (zh) 2022-09-20
MY183471A (en) 2021-02-19
SI3329965T1 (sl) 2025-07-31
PH12020500336A1 (en) 2021-02-22
IL275038B (en) 2022-11-01
CN108079291A (zh) 2018-05-29
HK1249466A1 (en) 2018-11-02
AU2018278866A1 (en) 2019-01-03
WO2012151248A3 (en) 2013-02-28
UA116189C2 (uk) 2018-02-26
US20180207279A1 (en) 2018-07-26
KR20200035503A (ko) 2020-04-03
SG194652A1 (en) 2013-12-30
KR20140145953A (ko) 2014-12-24
SMT201700508T1 (it) 2017-11-15
DOP2013000253A (es) 2013-12-31
CN103608071B (zh) 2017-12-26
ZA201806946B (en) 2022-03-30
US20200206353A1 (en) 2020-07-02
ZA201707158B (en) 2019-01-30
PT3329965T (pt) 2025-04-02
IL296838A (en) 2022-11-01
RS56397B1 (sr) 2017-12-29
IL275038A (en) 2020-07-30
EP2704798B1 (en) 2017-07-12
NZ617833A (en) 2016-04-29
JP2024098027A (ja) 2024-07-19
MY172735A (en) 2019-12-11
KR20250094743A (ko) 2025-06-25
JP7258941B2 (ja) 2023-04-17

Similar Documents

Publication Publication Date Title
TWI556828B (zh) 抗－α４β７抗體之調配物
TWI698254B (zh) 抗-α4β7抗體之調配物
HK40111834A (en) Formulation for anti-alpha4beta7 antibody
EA034583B1 (ru) ПРИМЕНЕНИЯ АНТИ-α4β7 АНТИТЕЛА
NZ617833B2 (en) Formulation for anti-?4?7 antibody
HK1195276B (en) Formulation for anti- alpha4beta7 antibody
HK1195276A (en) Formulation for anti- alpha4beta7 antibody